BRNS vs CALC

Barinthus Biotherapeutics plc vs CalciMedica, Inc. — Valuation Comparison 2026

BRNS

Pharmaceutical Preparations
Barinthus Biotherapeutics plc
Quality
6.0
out of 10
Value Trap
24
SAFE
Price
$0.68
Last close
Models
9/13
Active
VS

CALC

Pharmaceutical Preparations
CalciMedica, Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$0.82
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType BRNS Fair ValueBRNS Upside CALC Fair ValueCALC Upside
Bayesian DCF Intrinsic $0.94 +38.4% $0.45 -45.0%
First Chicago Scenario $0.29 -57.0% $0.57 -9.6%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.83 +168.5% $2.58 +215.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BRNS vs CALC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BRNS vs CALC — Which Stock Is More Undervalued?

BRNS scores higher with a 6.0/10 quality rating vs CALC's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Barinthus Biotherapeutics plc (BRNS) and CalciMedica, Inc. (CALC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BRNS currently trades at $0.68 with a QOC of 6.0/10, while CALC trades at $0.82 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).